Alexion Pharmaceuticals Overview
Pro stress-test →Alexion, a subsidiary of AstraZeneca, is a pharmaceutical company that discovers, develops and markets therapies for rare and life-threatening diseases. For almost 30 years, Alexion has been at the forefront of rare disease research, with a mission to support patients and families suffering from these conditions by discovering, developing, and selling life-changing drugs.
Strategic Profile
Pro stress-test →Alexion has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, with its franchise including Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. Research focuses on innovative molecules and targets in the complement cascade, while development work focuses on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology.
Competitive Landscape
Pro stress-test →Alexion competes in the rare disease immunology space against specialized biopharmaceutical companies and large pharma divisions focused on complement inhibition and monoclonal antibody therapeutics for orphan conditions.
Industry Context
Alexion Pharmaceuticals operates in Rare disease immunology therapeutics.
Key facts
Founded: 1992 · Headquarters: Boston, MA · Employees: N/A · Revenue: N/A · Market cap: N/A